Catheter Ablation of Ventricular Fibrillation.

Catheter ablation Premature ventricular contraction Purkinje system Sudden cardiac death Ventricular fibrillation

Journal

Heart, lung & circulation
ISSN: 1444-2892
Titre abrégé: Heart Lung Circ
Pays: Australia
ID NLM: 100963739

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 24 07 2018
revised: 29 08 2018
accepted: 05 09 2018
pubmed: 12 10 2018
medline: 17 1 2019
entrez: 11 10 2018
Statut: ppublish

Résumé

Ventricular fibrillation (VF) is a common and life-threatening arrhythmia resulting in sudden cardiac death (SCD). Due to the inherent challenges of mapping VF in humans, the underlying mechanisms that initiate and sustain this common arrhythmia are still poorly understood. In high-risk patients and survivors of SCD, implantable cardioverter defibrillators (ICD) play a central role in treating VF episodes, however, ICDs do not prevent VF recurrences and patients remain at risk of electrical storm and multiple shocks that are often refractory to escalation of medical therapy. More recently, the utility of catheter ablation (CA) has extended to the treatment of VF storms. This review will focus on updates in elucidating the mechanism of VF leading into the role and indication of CA as a treatment strategy.

Identifiants

pubmed: 30301669
pii: S1443-9506(18)31911-5
doi: 10.1016/j.hlc.2018.09.005
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

110-122

Informations de copyright

Copyright © 2018. Published by Elsevier B.V.

Auteurs

Robert D Anderson (RD)

Department of Cardiology, Royal Melbourne Hospital, Faculty of Medicine, Dentistry and Health Science, University of Melbourne, Melbourne, Vic, Australia.

Saurabh Kumar (S)

Department of Cardiology, Westmead Hospital, Sydney, NSW, Australia; Westmead Applied Research Centre, University of Sydney, Sydney, NSW, Australia.

Jonathan M Kalman (JM)

Department of Cardiology, Royal Melbourne Hospital, Faculty of Medicine, Dentistry and Health Science, University of Melbourne, Melbourne, Vic, Australia. Electronic address: jon.kalman@mh.org.au.

Prashanthan Sanders (P)

Centre for Heart Rhythm Disorders, Royal Adelaide Hospital Cardiology, The University of Adelaide, Adelaide, SA, Australia.

Frederic Sacher (F)

Hôpital Cardiologique du Haut-Lévêque, CHU de Bordeaux, Pessac, France.

Meleze Hocini (M)

Hôpital Cardiologique du Haut-Lévêque, CHU de Bordeaux, Pessac, France.

Pierre Jais (P)

Hôpital Cardiologique du Haut-Lévêque, CHU de Bordeaux, Pessac, France.

Michel Haïsaguerre (M)

Hôpital Cardiologique du Haut-Lévêque, CHU de Bordeaux, Pessac, France.

Geoffrey Lee (G)

Department of Cardiology, Royal Melbourne Hospital, Faculty of Medicine, Dentistry and Health Science, University of Melbourne, Melbourne, Vic, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH